7月15日，中国生物制药盘中上涨3.72%，报5.3港元，成交额1.06亿港元。
消息面上，公司7月14日公告，旗下北京泰德制药自主研发的1类新药TRD205已完成针对慢性术后神经病理性疼痛（CPSNP）的II期临床试验，凭借积极数据获CDE纳入突破性治疗药物名单。该药仅作用于外周，有望避免中枢神经系统类药物常见不良反应，且目前临床尚无针对CPSNP的专用治疗药物。同日，摩根士丹利重申"增持"评级，目标价维持7.8港元，计入阿斯利康及GSK首付款等商业授权收入后，上调公司各年每股基本盈测13.6%、5.5%及3.9%。此外，公司近期密集兑现BD成果，TQC3721海外授权阿斯利康总额最高达19亿美元，TQB3454上市申请亦已获CDE受理，创新管线进入集中收获期。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.